News
CGEN
1.880
-4.08%
-0.080
Weekly Report: what happened at CGEN last week (1109-1113)?
Weekly Report · 3d ago
Compugen Earnings Call Highlights Clinical Progress and Cash Runway
TipRanks · 5d ago
Compugen: Buy Reiterated as Clinical Catalysts and Partner Programs Support Unchanged $4 Price Target
TipRanks · 11/12 11:56
Compugen: COM701 Data On Track And Continued Bispecific Rilvegostomig Development
Seeking Alpha · 11/10 16:49
Oppenheimer Reaffirms Their Buy Rating on Compugen (CGEN)
TipRanks · 11/10 12:56
Stifel Nicolaus Remains a Buy on Compugen (CGEN)
TipRanks · 11/10 12:27
Compugen to Present UnigenX™ Platform at the 18th Annual PEGS Europe Summit
PR Newswire · 11/10 12:00
Compugen (CGEN) Q3 2026 Earnings Call Transcript
The Motley Fool · 11/09 17:13
Compugen Ltd. Reports Third Quarter 2026 Results
NASDAQ · 11/09 15:12
Compugen Reports Q3 Results as MAIA-Ovarian Trial Completes Enrollment
TipRanks · 11/09 12:33
Compugen Non-GAAP EPS of -$0.06 beats by $0.03, revenue of $3.8M beats by $2.83M
Seeking Alpha · 11/09 12:12
Compugen (CGEN) Reports Q3 Loss, Beats Revenue Estimates
NASDAQ · 11/09 12:10
Compugen Reports Third Quarter 2026 Results
PR Newswire · 11/09 12:00
Weekly Report: what happened at CGEN last week (1102-1106)?
Weekly Report · 11/09 10:22
Here are the major earnings before the open Monday
Seeking Alpha · 11/08 23:04
Compugen to Participate in November Investor Conferences
PR Newswire · 11/03 12:00
Weekly Report: what happened at CGEN last week (1026-1030)?
Weekly Report · 11/02 10:22
Compugen to Release Third Quarter 2026 Results on Monday, November 9, 2026
PR Newswire · 10/26 11:00
Weekly Report: what happened at CGEN last week (1019-1023)?
Weekly Report · 10/26 10:21
Weekly Report: what happened at CGEN last week (1012-1016)?
Weekly Report · 10/19 10:21
More
Webull provides a variety of real-time CGEN stock news. You can receive the latest news about Compugen through multiple platforms. This information may help you make smarter investment decisions.
About CGEN
Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company's pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates. These programs are focused on the development of cancer immunotherapy drugs with potential to harness the immune system to provide treatment solutions in areas of unmet medical needs in various cancer types and patient populations, both as monotherapy and in combination with other drugs. Its pipeline also includes a preclinical stage fusion protein autoimmune product candidate. Its fields of focus are oncology and immunology, with emphasis on its discovery capabilities on immuno-oncology.